Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...

Boehringer Ingelheim has acquired drug discovery and development company Nerio Therapeutics in a $1.3bn deal. The acquisition ...

DelveInsight’s 'Non-Cystic Fibrosis Bronchiectasis Pipeline Insight 2024' report provides comprehensive ... Haisco Pharmaceutical Group, Infex therapeutics, Boehringer Ingelheim, Regeneron ...

Ono Pharma and Boehringer Ingelheim both added to their cancer ... The Japanese drugmaker's clinical-stage pipeline does not currently feature any ADCs, which have transformed the treatment ...

Boehringer Ingelheim and Circle Pharma have entered ... The latest deal will strengthen the oncology pipeline of Boehringer, which includes a range of cancer cell-directed and immuno-oncology ...

This partnership is a significant step toward Boehringer Ingelheim’s goal of transforming cancer care. It bolsters the already robust oncology pipeline of cancer cell-directed and immuno ...

At its Second International Research & Development Press Conference, Boehringer Ingelheim unveiled a pipeline of unique oral anti-diabetic compounds in phase II and III, establishing the Company ...

Explore our latest breakthroughs in Wet Age-Related Macular Degeneration Research. Learn more about our innovative pipeline ...

It covers the pipeline drug profiles, including clinical and nonclinical ... of LYT-100 in patients with IPF in the first ...

Promising pipeline schizophrenia such as Ulotaront ... 2021. In March 2024, Boehringer Ingelheim and Sosei Group Corporation announced that they had entered a global collaboration and exclusive ...

Substantial enrollment progress in Phase 1b trial of SZN-043 in severe alcohol-associated hepatitis patients with proof-of-concept data expected ...